Cardiome Announces Licensing Agreement for XYDALBA(TM) (Dalbavancin Hydrochloride) to Support Planned Commercialization in Israel

VANCOUVER, June 21, 2017 -- (Healthcare Sales & Marketing Network) - Cardiome Pharma Corp. (NASDAQ: CRME / TSX:COM) today announced that its affiliate has signed an exclusive license and distribution agreement with Tzamal Medical Ltd. ("Tzamal")... Biopharmaceuticals, Licensing Cardiome Pharma, Tzamal Medical, XYDALBA, ABSSSI, dalbavancin
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news